Single View

Schnitzler-Syndrom (monocentric IIT)

Monday, 16. April 2018

A new study for Schnitzler syndrome

We started a new study for patients affected by Schnitzler syndrome. The treatment study examines the efficacy, safety, and tolerability of the drug Tocilizumab.

Tocilizumab is a medication that was approved for the treatment of rheumatologic diseases, including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (SJIA), and polyarticular juvenile idiopathic arthritis (PJIA), in both adults and children.  Signs of these diseases include an increased presence of inflammatory agents in the patients’ tissues as well as joint pain.

The aim of this study is to determine the ways in which the selective interleukin-6 receptor antagonist Tocilizumab affects the symptoms of Schnitzler Syndrome (many of these symptoms show a strong resemblance to above named rheumatologic diseases).

The study successfully started on 07/2017.

In case that you should have any questions regarding our clinical trials, please contact our study center at the Charité:

Clinic for Dermatology and Allergy
Tel: +49-30-450-618-293
Email: dealsz(at)charite.de